Myrobalan Therapeutics Names Grant Bogle to Board of Directors

Board strengthened by addition of financial, operational, and leadership expertise

Additional $9M in capital raised through subsequent Series A closing involving new investors

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announces the appointment of Mr. Grant C. Bogle to its Board of Directors. Mr. Bogle is a seasoned biotech executive with over three decades of operational experience in the biopharma industry and a strong focus on financial strategy, business development, corporate governance, and general management. The announcement comes approximately one month after the company raised an additional $9 million from three new investors through a subsequent closing of its Series A round, bringing total Series A funding to $33 million. The additional capital empowers the company to advance its lead CSF1R inhibitor program through first-in-human clinical testing and its demyelination-targeting GPR17 program through IND-enabling studies.

“Grant is a highly accomplished life sciences executive who has overseen the growth, commercialization, and sale of multiple successful biotechnology companies. I am thrilled to welcome him to our Board of Directors,” said Dr. Jing Wang, Chief Executive Officer of Myrobalan Therapeutics. “Grant's financial, operational, and leadership experience will be an invaluable asset to Myrobalan as we deploy capital to fuel our next phase of growth and progress our pipeline into the clinic.”

Mr. Bogle was formerly Chief Executive Officer at Epizyme, Inc., a Boston-based biotechnology company that developed TAZVERIK™ (tazemetostat), an FDA-approved oral EZH2 inhibitor for the treatment of relapsed/refractory follicular lymphoma. He assumed the CEO position in 2021 after having served on the Epizyme Board of Directors since 2019, and subsequently oversaw the 2022 acquisition of the company by Ipsen. Prior to that, Grant was senior vice president and chief commercial officer of TESARO, a publicly traded oncology company, which was acquired by GlaxoSmithKline in 2018 for $5.1 billion. Earlier, he served as senior vice president of pharmaceutical and biotech solutions at McKesson Specialty Health/U.S. Oncology, and was a senior executive at Millennium Pharmaceuticals, Viacord, Roche, and Knoll Pharmaceutical Company.

"It is a privilege to join Myrobalan's Board of Directors at such an exciting time in the company's journey," said Mr. Bogle. "Myrobalan's clear focus on central nervous system diseases, strong pipeline of brain-penetrant oral small molecule programs, and rapid R&D progress give this company tremendous potential to advance first-in-class and best-in-class therapeutics. I am eager to contribute my expertise and to work alongside this talented team to advance our mission of delivering transformative treatments to patients with severe CNS disorders."

Mr. Bogle also serves on the board of the American School for the Deaf, the oldest permanent school for the deaf in the United States. He holds a B.A. in economics from Dartmouth College, an MBA from Columbia Business School, and served as a fellow in the 2020 cohort of the Advanced Leadership Initiative at Harvard University.

About Myrobalan Therapeutics

Myrobalan Therapeutics is a preclinical stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, and innovative drug discovery tools, to create highly selective and brain-penetrant therapeutic candidates that are uniquely positioned for treating CNS conditions with significant unmet medical need. Myrobalan’s pipeline of novel remyelination and anti-neuroinflammation programs are being advanced with the strategic support of renowned institutional co-founders. Myrobalan is committed to a transformed future in which patients with degenerative CNS conditions can access safe and effective medicines offering restorative potential. For more information on Myrobalan Therapeutics, visit our website at myrotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725463217/en/